Opinion

Video

Beyond Glucose Control - The Expanding Role of Incretins in Diabetes and Obesity Management

In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist.

1:00 Effect of incretins on blood glucose and body weight

3:24 Evolution of GLP-1 agonists

7:45 Mechanism of tirzepatide- dual GLP-1/GIP agonist

10:35 Overview of SURPASS and SURMOUNT trials for tirzepatide

17:45 Benefits vs. risks of GLP-1 agonists

21:45 Sustainability of weight loss with incretin-based therapies

25:30 Future of metabolic diseases management

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Barry A. Borlaug, MD: Impact of Tirzepatide on Cardiorenal End-Organ Damage | Image Credit: Mayo Clinicn HFpEF
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Psoriasis podcast
3 KOLs are featured in this series.
Rahul Aggarwal, MD | Credit: LinkedIn
3 KOLs are featured in this series.
A panel of 3 experts on dry eye
© 2024 MJH Life Sciences

All rights reserved.